Interventions of Interest:

  • tirzepatide (Mounjaro™, Eli Lilly)

Tirzepatide has a novel dual GIP and GLP-1 receptor agonist mechanism of action and is seen as an add-on type 2 diabetes therapy; tirzepatide would achieve common thresholds for cost-effectiveness if priced between $5,500 – $5,700 per year.

 At the January 20 virtual meeting, ICER’s independent appraisal committee will review the evidence, hear further testimony from stakeholders, and deliberate over tirzepatide’s comparative clinical effectiveness, other potential benefits, and long-term value for money.

Final Documents

Final Evidence Report and Meeting SummaryDownload
Report-at-a-GlanceDownload
Final Policy RecommendationsDownload
Response to Public CommentsDownload
Draft Evidence ReportDownload

Jon Campbell, PhD, MS, ICER’s Senior Vice President for Health Economics stated:

“Tirzepatide is seen as an add-on therapy to metformin, like injectable semaglutide or empagliflozin. It has a novel GIP and GLP-1 receptor agonist mechanism of action. When compared to injectable semaglutide in one head-to-head trial, tirzepatide showed a greater decrease in HbA1c levels and weight, as well as in triglycerides and blood pressure. The evidence suggests that tirzepatide may deliver important health benefits, but data are still limited on long-term cardiovascular and renal effects.”

For questions, please contact Kelsey Gosselin, Program Manager, at kgosselin@icer.org.

View the Key Stakeholders List.